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Abstract
Background: The Long INterspersed Element-1 (L1, LINE-1) is the only autonomous mobile DNA element in
humans and has generated as much as half of the genome. Due to increasing clinical interest in the roles of L1 in
cancer, embryogenesis and neuronal development, it has become a priority to understand L1-host interactions and
identify host factors required for its activity. Apropos to this, we recently reported that L1 retrotransposition in HeLa
cells requires phosphorylation of the L1 protein ORF1p at motifs targeted by host cell proline-directed protein
kinases (PDPKs), which include the family of mitogen-activated protein kinases (MAPKs). Using two engineered L1
reporter assays, we continued our investigation into the roles of MAPKs in L1 activity.
Results: We found that the MAPK p38δ phosphorylated ORF1p on three of its four PDPK motifs required for L1
activity. In addition, we found that a constitutively active p38δ mutant appeared to promote L1 retrotransposition
in HeLa cells. However, despite the consistency of these findings with our earlier work, we identified some technical
concerns regarding the experimental methodology. Specifically, we found that exogenous expression of p38δ
appeared to affect at least one heterologous promoter in an engineered L1 reporter, as well as generate opposing
effects on two different reporters. We also show that two commercially available non-targeting control (NTC)
siRNAs elicit drastically different effects on the apparent retrotransposition reported by both L1 assays, which raises
concerns about the use of NTCs as normalizing controls.
Conclusions: Engineered L1 reporter assays have been invaluable for determining the functions and critical
residues of L1 open reading frames, as well as elucidating many aspects of L1 replication. However, our results
suggest that caution is required when interpreting data obtained from L1 reporters used in conjunction with
exogenous gene expression or siRNA.
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Background
The only active, autonomous mobile DNA element in
humans is the Long INterspersed Element-1 (LINE-1, L1)
retrotransposon, which is responsible for generating al-
most half of the human genome via insertion of its own
DNA and that of non-autonomous Short-INterspersed re-
peat Elements (SINES) [1]. These insertions, combined
with 3′ transductions, nonallelic homologous recombin-
ation and mobilization of cellular mRNAs, have had a
defining impact on genomic architecture, and the conse-
quences on gene regulation and human development are
largely unknown [2–5]. L1 activity is restricted to certain
cell types (reviewed in [6]), and retrotransposition is
thought to occur mainly in embryonic cells [7, 8],
pluripotent stem cells [9, 10], adult neuronal develop-
ment [11–15], and cancer [16–19]. Clinical interest in
L1 has increased due to its mutagenic and disease-
causing potential [11, 20–23], as well as its associ-
ation with cancer [16–19]. In addition, a growing
number of studies suggest that transposable elements
can be co-opted to serve fundamental physiological
functions [24–30]. Recent work has thus been aimed
at identifying cellular host factors required for L1
* Correspondence: pamela.cook@nih.gov
1Laboratory of Cell and Molecular Biology, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, 8 Center Drive,
Bethesda, MD 20892, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cook and Tabor Mobile DNA  (2016) 7:23 
DOI 10.1186/s13100-016-0079-3
expression, repression and reactivation. With respect
to this, our laboratory recently demonstrated that
host proline-directed protein kinase (s) (PDPKs) phos-
phorylate the L1 protein ORF1p on multiple PDPK
motifs required for L1 retrotransposition [31].
PDPK target motifs consist of serines or threonines
with a proline in the +1 position (S/T-P motifs), which
in ORF1p are: S18/P19; S27/P28; T203/P204; and T213/
P214. The PDPK family includes mitogen-activated pro-
tein kinases (MAPKs), cyclin dependent kinases (CDKs)
and glycogen synthase kinase 3 (GSK3). Prior to our
finding that the phosphorylation of ORF1p by PDPKs is
necessary for L1 activity, several studies reported associ-
ations between L1 and the PDPK p38 [32–34], a MAPK
that exists in four different isoforms, α, β, γ and δ [35].
Moreover, the expression of one isoform, p38δ, can be
induced in primary cell cultures via exogenous expres-
sion of ORF1p [34].
Given these associations between L1 and the PDPK
p38, as well as our previous findings that host PDPKs
are required for L1 retrotransposition, we decided to in-
vestigate the role of each p38 isoform on ORF1p phos-
phorylation and L1 activity. Although our studies are
ongoing, we believe that dissemination of our present
findings and their associated experimental pitfalls will be
useful to the L1 research community. We report here
that: 1) different populations of HeLa cells can result in
different experimental outcomes; 2) two presumably
complementary L1 retrotransposition reporter assays
produced conflicting results when coupled with exogen-
ously expressed p38δ; and 3) two different non-targeting
control (NTC) small interfering RNA (siRNA) sequences
differentially affected measured L1 activity.
Results
MAPK p38δ phosphorylates ORF1p on S/T-P motifs
We first determined whether activated wild type p38δ
(WT, Invitrogen) could phosphorylate ORF1p on its S/
T-P motifs, which are required for robust L1 activity
[31]. In vitro radioactive kinase assays revealed that
p38δ-WT exclusively phosphorylated bacterially purified
ORF1p on these residues, as an ORF1p carrying muta-
tions at all four motifs, S18A/S27A/T203G/T213G
(AAGG), was not phosphorylated (Fig. 1a top). We next
tested the ability of p38δ-WT to phosphorylate the
ORF1p mutants S18A/S27A (AA) and T203G/T213G
(GG), and found that the majority of phosphorylation
occurred on the GG mutant, which retained both serine
motifs (Fig. 1a top).
In order to compare the degree of phosphorylation at
each motif, we constructed a series of mutants, each
bearing only one intact S/T-P motif: SAGG (S27A/
T203G/T213G); ASGG (S18A/T203G/T213G); AATG
(S18A/S27A/T213G); and AAGT (S18A/S27A/T203G).
S27 (ASGG) was phosphorylated by p38δ-WT to the
greatest extent (Fig. 1a top). T213 (AAGT) was phos-
phorylated to approximately the same degree as S18
(SAGG), but p38δ-WT showed almost no activity on
T203 (AATG). Of note, results from the kinase predic-
tion program NetPhosK 1.0 [36] indicated that unspeci-
fied p38 isoforms were expected to target ORF1p at S18,
T203 and T213, but not S27.
Constitutively active p38δ-F324S retains ORF1p substrate
specificity
Various p38δ mutants that retain some degree of consti-
tutive activity independent of phosphorylation by their
activating upstream kinases in the MAPK pathway have
been described [37]. In those studies, the constitutively
Fig. 1 The MAPK p38δ phosphorylates ORF1p on S/T-P motifs
required for L1 retrotransposition. a ORF1p-WT or S/T-P mutants
(200 μM), purified from E. coli, were incubated with 85 nM activated
p38δ-WT (top) or the constitutively active p38δ mutant F324S (bottom)
in the presence of [γ-32P]-ATP; bands on autoradiogram show 32P
incorporation into ORF1p. ORF1p mutants are S18A/S27A/T203G/
T213G (AAGG), S18A/S27A (AA), T203G/T213G (GG), S27A/T203G/T213G
(SAGG), S18A/T203G/T213G (ASGG), S18A/S27A/T213G (AATG) and
S18A/S27A/T203G (AAGT). b ORF1p-WT was incubated with activated
p38δ-WT, p38δ-F324S, an inactive p38δ mutant D176A, or no kinase in
reactions as described in (a). c A Coomassie-stained gel shows each
ORF1p construct (approximately 100 ng) purified from E. coli.
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active mutant p38δ-F324S retained the substrate specifi-
city of activated p38δ-WT for glutathione S-transferase
activating transcription factor 2 (GST-ATF2) in vitro
when p38δ-F324S was purified from bacteria or immu-
noprecipitated from HEK293 cell lysates. We found that
bacterially purified p38δ-F324S also exhibited wild type
substrate specificity for ORF1p’s S/T-P motifs (Fig. 1a
bottom). In addition, we tested the mutant p38δ-D176A,
which was reported to have no activity on GST-ATF2
when purified from bacteria but greater activity than
p38δ-WT when immunoprecipitated from HEK293 cells
[37]. Bacterially purified p38δ-D176A barely phosphory-
lated ORF1p in vitro compared to p38δ-WT or p38δ-
F324S (Fig. 1b). Figure 1c shows each ORF1p construct,
purified from E. coli, used for the in vitro kinase assays.
L1 reporter assays
Given our findings that p38δ specifically phosphorylated
ORF1p S/T-P motifs, we proceeded to determine the ef-
fect of p38δ on L1 retrotransposition. To assess this, we
used two previously characterized L1 reporter assays.
The original L1 retrotransposition reporter, JM101 (a
kind gift from Dr. John Moran), relies on the splicing of
an artificial intron from an L1-borne neomycin-resistant
gene and its L1-mediated conversion into genomic DNA
to produce cell foci resistant to the neomycin analog
G418 [38]. Specifically, the reporter contains a full-
length L1 element driven by the cytomegalovirus (CMV)
promoter and an mneo cassette that encodes the
neomycin-resistant gene (neo), driven by a Simian virus
40 (SV40) promoter located within the 3′ untranslated
region (UTR) of L1 (Fig. 2 top). The neo gene product,
also known as aminoglycoside 3′-phosphotransferase-II
(APH (3′)-II), phosphorylates and thereby inactivates
G418. Selection with G418 is begun approximately three
days following transfection of the reporter plasmid into
retrotransposition-competent cells and is continued for
10–12 days. The arrangement of the neo gene in JM101
ensures that only cells that have undergone retrotran-
sposition by the L1 reporter element will express APH
(3′)-II. The coding sequence for neo and its promoter
are located on the antisense strand in the 3′ untrans-
lated region of L1. Within this sequence is the engi-
neered artificial intron, but it can only be spliced from
the L1 sense RNA driven by the L1 promoter due to the
orientation of the splice donor (SD) and splice acceptor
(SA) sequences. Once spliced, the L1 RNA is retrotran-
sposed into cDNA and inserted into the genome. After
synthesis of the complementary DNA strand, which con-
tains the spliced neo template, the transcript for APH
(3′)-II can be initiated from the antisense promoter.
The more recently developed single-vector dual lucifer-
ase L1 reporters (kind gifts from Dr. Wenfeng An) are
based on the same principle as the mneo reporter, but
instead of neo they contain the gene for Firefly luciferase
(Fluc). Fluc is also driven by an SV40 promoter and inter-
rupted by an intron to monitor retrotransposition (Fig. 2,
lower schematics) [39]. In addition, this reporter contains
an internal control gene expressing Renilla luciferase (Rluc)
driven by a Herpes simplex virus thymidine kinase (HSV-
TK) promoter. Constitutively active Rluc expression is
intended as a normalizing control for variations in cell
plating, transfection efficiency and survival. Four days fol-
lowing transfection, cells are lysed and retrotransposition is
reported as a function of Rluc-normalized Fluc lumines-
cence. The three single-vector luciferase reporters used in
this study were: pYX017, which contains an L1 element
driven by a hybrid CAG promoter consisting of the CMV
enhancer fused with a modified chicken beta-actin pro-
moter and a splice element from the rabbit beta-globin
gene [40]; pYX014, which contains only the native L1 pro-
moter in the 5′UTR; and pYX015, a negative control,
which is identical to pYX014 except that it carries two mis-
sense mutations in ORF1p and is thus retrotransposition-
incompetent [38, 39].
Constitutively active p38δ increases G418-resistant
colonies
Consistent with our in vitro results and our previous
findings that the phosphorylation of ORF1p S/T-P mo-
tifs is required for robust L1 activity, we found that ex-
ogenous expression of the constitutively active p38δ-
F324S (FS) appeared to increase L1 retrotransposition in
the G418-based assay relative to an empty vector control
(EV), while p38δ-D176A (DA), which failed to appre-
ciably phosphorylate ORF1p in vitro, inhibited L1 (Fig. 3a
top). Surprisingly, p38δ-WT (WT) also repressed forma-
tion of G418-resistant colonies (Fig. 3a top left). These
effects did not appear to be a result of altered cell viabil-
ity, as only p38δ-D176A somewhat affected cell growth
(Fig. 3a bottom left). To determine whether the observed
decrease in colony density resulting from p38δ-WT
overexpression might be due to effects of the expression
vector on cotransfection efficiencies, we cotransfected
an expression plasmid for the enhanced green fluores-
cent protein (EGFP, a kind gift from Dr. Birong Shen)
with either the pcDNA empty vector, p38δ-WT or p38δ-
F324S. Neither p38δ-WT nor p38δ-F324S appreciably
altered EGFP fluorescence compared to the empty vec-
tor (Fig. 3a right).
The inhibition of L1 by p38δ-WT may be explained by
the fact that p38, like other MAPKs, relies on a complex
network of docking interactions with many proteins, in-
cluding substrates, upstream activating MAPK kinases,
phosphatases and scaffolding and regulatory factors.
These interactions collectively synchronize the activation
and localization of p38 via feedback loops and crosstalk
with other pathways [[41] and references therein]. Thus,
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a pool of excess, unactivated p38δ-WT could perturb this
regulatory system, or may simply compete with the popula-
tion of endogenous activated p38, resulting in inhibition of
L1. Consistent with this possibility are several studies that
showed expression of a nonfunctional p38 has a dominant
negative effect on endogenous p38 activity [42–46]. In
addition, during some of our own preliminary experiments,
we found on rare occasion that exogenous p38δ-WT
slightly increased rather than decreased the number of
G418-resistant colonies (unpublished data), further suggest-
ing that the effect of exogenous p38δ-WT could depend on
cellular conditions that affect the p38 pathway. For ex-
ample, confluent stock cultures, as opposed to proliferating
cultures, have been found to activate endogenous p38α,
with effects lasting up to 48 h after re-plating [47]. How-
ever, our investigation of this and several other routine tis-
sue culture variables, including the amount of time cells
were exposed to trypsin during sub-culturing, the presence
or absence of antibiotics in culture media, lot-to-lot varia-
tions in fetal bovine serum (FBS), passage number or over-
all time in culture, revealed no correlation with the effect of
exogenous p38δ on L1 activity (unpublished data). A previ-
ous report indicated that individual HeLa clones can exhibit
varying degrees of retrotransposition activity and that cer-
tain clones may grow to dominate a mixed culture over
time [48]. This phenomenon may also bear on how exogen-
ous host factors impact L1 activity.
Effects of MAPK p38δ-WT differ depending on the L1 re-
porter assay used
As part of our efforts to understand the effects of p38δ-
WT on L1, we used the single-vector dual luciferase assay
in parallel with the G418-based assay (i.e. cells were
plated from a common suspension and transfected
simultaneously using the same reagents). Data from dual
luciferase assays are typically normalized to Rluc expres-
sion and reported as a ratio of Fluc/Rluc luminescence.
Using this method in an experiment done in parallel with
the G418-based assay in Fig. 3a, we found that p38δ-WT,
p38δ-F324S, and, surprisingly, p38δ-D176A, increased L1
retrotransposition by 5, 7.7 and 7 fold, respectively
(Fig. 3b). However, the Fluc/Rluc luminescence ratio is
valid only if the expression of Rluc is independent of the
experimental treatment. It is obvious from the individual
luminescence data for Fluc and Rluc shown in Figs. 3c
and d that p38δ expression dramatically affected Rluc lu-
minescence. Such a decrease in Rluc in the absence of a
corresponding decrease in cell survival or transfection effi-
ciency would thus artificially inflate the Fluc/Rluc ratio.
As shown previously, cell growth was not detectably af-
fected by p38δ-WT or p38δ-F324S, and we detected no
differences in cell densities in any wells during the course
of the luciferase assay. Moreover, we found no effect from
p38δ-WT or p38δ-F324S in the previous cotransfection
efficiency control experiment using EGFP. Combined,
these data strongly suggest that Rluc, driven by the HSV-
TK promoter, is an inadequate normalizing control for
these experiments.
Rluc expression notwithstanding, Fluc, like APH (3′)-
II, reports on raw retrotransposition events and would
thus be expected to produce results paralleling those of
the G418 assay under similar experimental conditions. If
we then consider only Fluc luminescence, the effects of
p38δ-F324S and p38δ-D176 roughly coincide in direc-
tion if not degree with those observed in the G418 assay.
However, p38δ-WT appears to affect the two reporters
differently, inhibiting G418-resistant colony formation
but slightly increasing Fluc luminescence (Figs. 3a, c and
Fig. 2 Schematic of L1 reporter plasmids. All reporters contain a full-length L1 element with 5′ and 3′ UTRs (orange), ORF1 (pink), intergenic region
(gray), ORF2 (blue) and a retrotransposition reporter (yellow) interrupted by an artificial intron (purple) with splice donor (SD) and acceptor (SA) sites. In
JM101, L1 is driven by the CMV promoter (green), and in pYX017 by the hybrid CAG promoter (green). pYX014 contains only the native L1 promoter in
the 5′UTR, and pYX015 is identical to pYX014 except for two missense mutations (R261A/R262A) [38] in ORF1p, rendering pYX015 incompetent for
retrotransposition. The reporter in JM101 is an mneo cassette driven by the SV40 promoter (green) located within the 3′ UTR. The pYX017, pYX014 and
pYX015 constructs contain a Firefly luciferase reporter (Fluc), also driven by SV40 (green), as well as a gene for Renilla luciferase (Rluc; aqua) driven by
the HSV-TK promoter (green)
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Fig. 3 Effects of p38δ on two different L1 reporter assays. a Top rows show duplicate wells of Giemsa-stained G418-resistant colonies resulting from
transfection of the L1 reporter JM101 in the presence of pcDNA mammalian expression vectors for: empty vector (EV), p38δ-WT (WT), p38δ-F324S (FS)
or p38δ-D176A (DA). Bottom row shows the effect of each pcDNA expression vector on cell growth. The right panel indicates fluorescence intensities
obtained from cotransfection of EGFP with each indicated p38δ construct or empty vector; results from duplicate wells are shown. b Relative Fluc/Rluc
luminescence ratios obtained from lysates of HeLa cells transfected with the L1 reporter plasmid pYX015 or pYX017 in the presence of indicated pcDNA
mammalian expression vectors. Three biological replicates are shown for each experimental condition; error bars represent the SEM from two technical
replicates (defined as two distinct samples taken from each biological sample). The graph at right shows the average of three biological replicates shown
separately in the left panel; error bars indicate the SEM, n= 3 biological replicates. c Individual luminescence values are shown for Fluc (blue) and Rluc (red)
used to calculate the Fluc/Rluc ratios from pYX017 in (b); technical replicates are side-by-side; biological replicates are indicated in subscript. d Mean Fluc
and Rluc luminescence values were derived by first averaging the technical replicates for each biological sample (n= 2), and then averaging the resulting
values of each biological replicate; error bars represent the SEM of biological replicates, n= 3
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d left). As with the G418 assay, our preliminary experi-
ments using the dual luciferase assay sometimes showed
an outlier effect of p38δ-WT, but in this case the outlier
was repression of Fluc (unpublished data). Although sub
clonal HeLa populations may have been a contributing
factor in those experiments, which utilized different
stocks of cells, it would not explain differential effects of
p38δ-WT on two reporters in experiments performed in
parallel using a common suspension of HeLa cells.
Two questions thus arose: 1) why did p38δ-WT pre-
dominantly decrease colony numbers in the G418 assay
but increase Fluc luminescence, while the effects of
p38δ-F324S and p38δ-D176A remained consistent be-
tween the two reporters, and 2) what is the cause of de-
creased Rluc expression in the presence of p38δ?
With respect to the first question, it may be significant
that variations were most evident in response to p38δ-WT
since it, unlike F324S, would be dependent on a network of
cellular factors for activation. This possibility notwithstand-
ing, if the inhibitory effects of p38δ-WT in the G418-based
assay arose from competition with endogenous p38δ, one
would expect equivalent competition, not activation, with
the pYX017 reporter. Since this was not what we observed,
we then considered variables in the assays themselves that
might explain the differential effects of p38δ-WT.
The first and most obvious difference between the two
reporters is that L1 is driven by a CMV promoter in
JM101 but a CAG promoter in pYX017, though the
CAG promoter contains a CMV enhancer element
(Fig. 2). CMV promoters can be affected by some p38
isoforms [49–53], but we did not observe a significant
effect of p38δ-WT or p38δ-F324S on EGFP, which is
also driven by a CMV promoter. To address whether the
increase in Fluc luminescence stemmed from effects of
p38δ on the CAG promoter, we used the pYX014 con-
struct, which is identical to pYX017 except that it relies
on the native L1 promoter in the 5′ UTR for L1 expres-
sion instead of CAG (Fig. 2). Using JM101 in parallel
with pYX014, we again found that p38δ-WT inhibited
formation of G418-resistant colonies (Fig. 4a), while
both p38δ-WT and p38δ-F324S increased Fluc lumines-
cence from pYX014 by 1.5 and 2.2 fold, respectively
(Figs. 4b left and c), compared to 1.3 and 1.5 fold from
pYX017 (Fig. 3d left). Since p38δ-WT increased Fluc in
both pYX014 and pYX017, the effect of p38δ-WT ap-
pears to be independent of the CAG promoter in
pYX017. We eliminated p38δ-D176A from this and fur-
ther experiments given its effect on cell growth (Fig. 3)
as well as the report that, despite its inactivity in vitro, it
can be activated in HEK293 cells [37], making its effects
on L1 uninterpretable, particularly given the inhibitory
effect of p38δ-WT on G418-resistant colony formation.
Regarding the effect of p38δ on Rluc luminescence, we
considered three possible explanations: 1) cell death; 2)
transcription or translation interference from pcDNA-
p38δ; or 3) inhibition of the Rluc HSV-TK promoter.
As stated earlier, we found no evidence of cell death,
despite a 76–94% decrease in Rluc luminescence using
pYX017 (Figs. 3c and d right) and similar decreases with
pYX014 (Fig. 4b right and c). Moreover, the decrease in
Rluc luminescence from the retrotransposition defective
pYX015 (Fig. 4c) ruled out the possibility that rampant
L1 activity severely compromised the cells, an event the
G418-based assay could have potentially missed.
The second option was that decreased Rluc lumines-
cence resulted from generalized transcription and/or
translation interference from the cotransfected plasmids.
Competition for cellular factors can be relevant at mul-
tiple points, including promoter binding, transcription ini-
tiation, elongation or translation [54–57]. For example,
the different levels of Rluc luminescence from pYX017
(Fig. 3) compared with pYX014 (Fig. 4) might suggest that
the highly active heterologous CAG promoter in pYX017
competed with factors required by the HSV-TK promoter
driving Rluc in pYX017. Also, the empty vector control
lacked an optimized Kozak sequence, which may have
rendered it less effective at competing for translational
machinery than the p38δ constructs. To determine if the
kinase-containing plasmids competed with pYX017 for
factors necessary for Rluc expression, we cotransfected
the L1 reporter with plasmids encoding constitutively ac-
tive MAPK-kinases (MAPKKs) MKK3b-S288E/T222E
(M3) or MKK6-S207E/T211E (M6), which are specific up-
stream activators of p38 isoforms [58–60]. Unlike p38δ,
each MKK upregulated Rluc (Fig. 5a right and b). As ex-
pected, each MKK also increased Fluc (Fig. 5a left), pre-
sumably via activation of an endogenous p38. Neither of
the MKKs had any effect on cell growth (Fig. 5c). These
results strongly suggest that inhibition of Rluc by p38δ is a
specific rather than indiscriminate effect.
The ability of p38δ to inhibit the Rluc HSV-TK pro-
moter was not empirically determined by us, but mul-
tiple reports show that HSV-TK promoters, including
those driving Renilla, can be perturbed by multiple ex-
perimental conditions [61–64]. These include the ex-
pression of the Sp1 transcription factor [64], which is
upregulated by p38 [65]. We consider the potential ef-
fects of p38 on the HSV-TK and SV40 heterologous pro-
moters, as well as other elements of the L1 reporters, in
greater detail in the discussion.
Two non targeting control siRNAs differentially affect
reported L1 activity
While investigating the effect of p38δ on L1 retrotran-
sposition, we performed siRNA experiments using a
SMARTpool mixture against p38δ (Dharmacon, M-
003591-02-0005) and the NTC siRNA #3 (Dharmacon).
Although the siRNA against p38δ dramatically reduced
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the number of G418-resistant colonies relative to NTC
#3, RT-PCR showed no significant knockdown of the
p38δ transcript (data not shown). Interestingly, however,
NTC #3 considerably increased colony density relative
to the mock control (Fig. 6a left). EGFP fluorescence
from cells pretreated with siRNA prior to transfection
suggested that the siRNA had little impact on transfec-
tion efficiency (Fig. 6a right). Given these unexpected re-
sults, we tested an additional control siRNA, NTC #5,
also from Dharmacon. In marked contrast to NTC #3,
NTC #5 dramatically reduced G418-resistant colonies
relative to the mock control (Fig. 6b top). Neither NTC
dramatically affected cell growth, though NTC #3 had a
slight inhibitory effect (Fig. 6b bottom). It is notable that
unlike p38δ-WT, the NTC siRNAs exerted their respect-
ive effects similarly on both Fluc luminescence and G418-
resistant colony formation (Fig. 6b top, c left and d).
However, L1 activity as reported by the Fluc/Rluc ratio
appears to be decreased by NTC #3 rather than in-
creased (Fig. 6c). We did not further investigate poten-
tial causes for these results. Information on
Dharmacon’s website states that each NTC is reported
to contain a minimum of 4 mismatches to all human,
mouse and rat genes and to have minimal effects in
genome-wide targeting via microarray analyses. We did
not test Dharmacon’s NTC #1, as it was reported to in-
crease cell growth (personal communication, Dharma-
con), nor NTC #2 or #4 due to their targeting of Firefly
luciferase (Dharmacon website).
Discussion
Engineered L1 reporter assays have tremendously advanced
the field of L1 research, allowing investigators to examine
key details of the retrotransposition process [66]. Through
mutational analyses, critical amino acids in ORF1p and
ORF2p have been identified, leading to a greater under-
standing of the form and functions of these proteins and
their roles in L1 retrotransposition. Investigations of L1 in-
sertion sites, 5′ truncations, untranslated regions, native L1
promoters and the poly (A) tail have all been made possible
by these assays, as have numerous comparative evolution-
ary studies of extinct L1 fossils in the human and mouse
genomes. Our own work on the role of ORF1p phosphoryl-
ation would not have been possible without these reporters.
Importantly, we have not observed variation in relative
differences between an L1-WT control and any L1 mu-
tant in our history of working with L1 reporter plasmids.
In other words, any mutant L1 construct we have made
consistently exhibits the same degree of change in
G418-resistant colonies relative to a WT control within
a given experiment, independent of differences in cell
populations. Thus, the L1 reporters are particularly reli-
able for investigating cis aspects of L1—the purpose for
which the original reporter was designed. However, the
results presented here strongly suggest that data derived
from L1 reporters when used in conjunction with ex-
ogenous gene expression or siRNA to investigate the
roles of host factors may be challenging to interpret. Al-
though we have not exhaustively investigated possible
Fig. 4 p38δ increases Fluc independent of a heterologous promoter. a Duplicate wells containing G418-resistant colonies resulting from transfection of
HeLa cells with the L1 reporter JM101 in the presence of pcDNA mammalian expression vectors for: empty vector (EV), p38δ-WT (WT) or p38δ-F3324S (FS).
b Mean Fluc (left) and Rluc (right) luminescence values obtained from lysates of HeLa cells transfected with the L1 reporter plasmid pYX014 in the presence
of indicated pcDNA mammalian expression vectors. Averages were derived from raw data shown in (c) by first averaging technical replicates for each
biological sample (n= 3), and averaging biological replicates; error bars represent SEM of biological samples, n= 2. c Individual luminescence values are
shown for Fluc (blue) and Rluc (red) used to calculate averages in (b); technical replicates are side-by-side; biological replicates are indicated with subscripts
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factors that would account for our results, we feel these
data are nonetheless informative and potentially timesav-
ing for other researchers intending to use these
approaches to investigate interactions between L1 and
its host.
Our efforts to determine the effect of p38δ on L1
retrotransposition using engineered L1 reporters under-
score the complexities inherent in such endeavors. The
p38 signaling pathway itself is extremely complex, with
different isoforms having unique, overlapping or compet-
ing functions depending on the cell type, or even within
the same cell under different conditions [35, 67–69]. This
complexity is compounded by the possibility that different
p38 isoforms may have competing specificities and
functional outcomes on ORF1p and other substrates rele-
vant to L1 activity, as well as on heterologous promoters
in L1 reporters.
A case in point is the repression of Rluc by exogenous
p38δ. Previous reports show that p38 can activate late
HSV promoters [70] as well as the transcription factor
Sp1 [65], which both binds [71] and activates the HSV-TK
promoter [61, 64]. These studies would suggest that if
p38δ had an effect on HSV-TK, it would be activation, not
repression. However, this assumption would be an over-
simplification given the complexity of p38 signaling and
reports that p38 isoforms can compete with one other
with opposing effects [68]. An alternative possibility is that
over-expression of exogenous p38δ perturbed constitutive
Fig. 5 MKK3b2E and pcDNA-MKK62E increase Rluc luminescence. a Mean Fluc (left) and Rluc (right) luminescence values obtained from lysates of
HeLa cells transfected with the L1 reporter plasmid pYX015 or pYX017 in the presence of pcDNA-MKK3b2E (M3) or pcDNA-MKK62E (M6). Averages
were derived from data shown in (b) by first averaging technical replicates for each biological sample (n = 2), then using this value to average
biological replicates; error bars represent SEM of biological samples, n = 3. b Individual luminescence values are shown for Fluc (blue) and Rluc
(red) obtained from lysates transfected with pYX015 or pYX017 and the indicated pcDNA expression vectors; technical replicates are side-by-side;
biological replicates are indicated with subscripts. c Wells show effects on cell growth in response to expression of pcDNA-MKK3b2E (M3) or
pcDNA-MKK62E (M6)
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activation of the HSV-TK promoter by interfering with a
different endogenous p38 isoform. This possibility is sup-
ported by two observations. First, each p38δ construct re-
pressed Rluc luminescence despite the fact that each has
widely varying catalytic activities in vitro as well as differ-
ent effects on L1 activation. Equivalent effects from each
p38δ construct would be expected only if the effect were
mediated by something other than their catalytic kinase
activity; e.g., competition for docking interactions with
limiting regulatory factors required by other p38 isoforms.
Second, since MKK3b-2E and MKK6-2E selectively acti-
vate only p38 isoforms [72], their activation of Rluc
strongly suggests that HSV-TK is indeed activated by an
endogenous p38 isoform, but not p38δ. Combined, these
data indicate that the ability of both active and inactive ex-
ogenous p38δ to repress the HSV-TK promoter derives
from competition for host regulatory proteins by another,
endogenous p38 isoform.
Fig. 6 NTC siRNAs have differential effects on L1 reporter assays. a Wells show G418-resistant colonies resulting from transfection of the L1 reporter
JM101 in the presence of no siRNA (mock, with transfection reagent only) or 10 nM NTC #3 siRNA. Graph at right shows EGFP fluorescence from cells
pretreated with 10 nM NTC #3 siRNA or mock (M); results from duplicate wells are shown. b Top row shows G418-resistant colonies resulting from the
transfection of the L1 reporter JM101 in the presence or absence of 25 nM of indicated siRNA; bottom row shows effect of 25 nM of indicated siRNA
on cell growth. c Mean Fluc (left) and Rluc (second from right) luminescence values obtained from lysates of HeLa cells transfected with the L1 reporter
pYX017 in the presence of no siRNA (M) or 25 nM NTC #3 or NTC #5; averages were derived from data shown in (d) by first averaging technical
replicates for each biological sample (n = 2), then using this value to average biological replicates; error bars represent SEM of biological samples, n = 3;
average Fluc/Rluc ratios (third from right) are also shown. d Individual luminescence values are shown for Fluc (blue) and Rluc (red) obtained from
lysates of HeLa cells transfected with pYX017 and the indicated siRNA; technical replicates are side-by-side; biological replicates are indicated
with subscripts
Cook and Tabor Mobile DNA  (2016) 7:23 Page 9 of 15
While most of our focus here has been on possible
sources of artifact arising from the single vector dual lu-
ciferase assay, p38δ-WT and p38δ-F324S similarly acti-
vated Fluc in those assays; it was only in the G418-based
assay where contradictory results between p38δ-WT and
F324S were observed, with significant inhibition of ap-
parent retrotransposition in response to p38δ-WT but
strong activation by F324S. Since p38δ-WT gave con-
flicting results in these assays, it may be worth discuss-
ing potentially relevant variations between the assays.
One notable difference is the lack of the Epstein-Barr nu-
clear antigen 1 (EBNA1) gene and the Epstein-Barr virus
(EBV) origin of replication on the single vector dual lucifer-
ase reporters, which were not required due to the shorter
experimental time relative to the G418-based assay [39].
EBNA1, however, contains multiple phosphorylation sites
required for the maintenance of plasmids and transcrip-
tional activation [73, 74]. Specifically, the EBNA1 nuclear
localization sequence contains two S/T-P motifs, whose
phosphorylation is required for nuclear import [73–75]. Al-
though at least one of these motifs is thought to be targeted
by CDKs [75], it is possible that phosphorylation of one or
both S/T-P motifs is perturbed by exogenous p38δ-WT
expression via competition for regulatory factors.
Another difference between the two assays is their re-
spective reporter genes. The G418-based assay relies on
expression of APH (3′)-II to monitor L1 retrotransposi-
tion. However, in addition to inactivating aminoglycosides
via phosphorylation, two APH isoforms have also been
found to phosphorylate proteins. Although it is not known
whether the neomycin resistance gene APH (3′)-II or the
hygromycin resistant gene APH (4)-I, also present on
JM101, can similarly target cellular proteins, caution has
been urged in their use as selectable markers if such
activity might interfere with the experimental design [76].
A source of potential artifact for both assays is the SV40
promoter, which drives the neo and Fluc reporter cas-
settes. As noted earlier, p38 is known to activate the tran-
scription factor Sp1, which in addition to binding the
HSV-TK promoter also binds and activates the SV40 early
promoter [77]. Moreover, the SV40 promoter contains
binding sites for AP-1 transcription factors [78, 79], which
are activated by the isoform p38β but can be inhibited by
p38γ or p38δ [68]. Thus, perturbed expression, in either
direction, of an already spliced and integrated Fluc gene
could falsely report on retrotransposition events. It is un-
clear, however, whether an increase above a given baseline
expression of APH (3′)-II would alter colony viability or
growth during G418 selection. Also of note, a recent study
of the effects of heavy metals on L1 found that cobalt in-
creased the activity of the SV40 promoter in HeLa cells
but decreased its activity in human fibroblasts and the hu-
man neuroblastoma cell line BE (2)-M17 [80], indicating
that heterologous promoters can be differentially affected
by the same variables in different cell lines. This raises the
possibility that different clonal populations of the same
cell type might also respond differentially to exogenous
factors.
Regarding potential effects arising from the CMV pro-
moter, although p38δ did not appear to affect expression
of the CMV-driven EGFP, we imaged EGFP expressing
cells 24 h post transfection for the purpose of monitor-
ing transfection efficiencies, whereas G418 selection was
begun three days post transfection. Thus, though EGFP
appeared to report equivalent transfection efficiencies, it
may not have accurately reflected cumulative effects of
p38δ on a CMV promoter after 72 h. With respect to
transfection efficiency controls, the potential for exogen-
ous factors to impact these reporters remains an issue,
as was demonstrated by the effects of p38δ on Rluc lu-
minescence, which is the transfection efficiency reporter
for the luciferase assay, versus no effect on from p38δ
on EGFP fluorescence, which is also a common reporter
for transfection efficiencies in a variety of assays.
The use of siRNA to probe the functions of cellular
genes is a common technique, but the potential for off-
target effects is a major drawback. This is typically
accounted for by using NTC siRNA, with the assumption
that NTC and target siRNAs produce equivalent off-target
effects. While this may be true for some experimental sys-
tems, the dramatically different effects of NTC #3 and
NTC #5 on L1 reporter output suggest a potential prob-
lem when these methods are used together. First, interpre-
tations regarding the effect of a targeting siRNA based on
comparison to a given NTC would be skewed if the siR-
NAs produced dissimilar off-target artifacts. This is true
even if one confirms knockdown of the target gene. For
example, if the target siRNA knocks down a gene of inter-
est (GOI) by 50% and decreases L1 retrotransposition by
50%, one might conclude that knocking down the GOI
decreases L1 activity if control siRNA #3 was the non-
targeting control. In contrast, if one happened to use con-
trol siRNA #5, the conclusion would have been the oppos-
ite; i.e. that knockdown increased L1 activity.
In addition, it is possible that targeting siRNAs could
induce the same types of artifacts we observed with the
NTC siRNAs. For example, despite a hypothetical paral-
lel 50% knockdown of the GOI and L1 activity, the de-
crease in L1 activity may have been due solely to off-
target effects unrelated to gene knockdown. Similarly, it
may be possible that off-target effects that increase ap-
parent L1 activity could mask a genuine inhibitory effect
mediated by gene knockdown. Our data with NTC #3
and #5 show that it is unreliable to control for such off-
target effects by using non-targeting control siRNAs
alone, as their effects can vary dramatically and may not
be equivalent to those induced by targeting siRNAs. The
most well- established method for confirming that results
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from targeting siRNA are due to GOI knockdown is the
cotransfection of siRNA-resistant rescue plasmids. How-
ever, the interpretation of these results may still be com-
plex in certain situations, as evidenced by our finding
that p38δ-WT can both repress and activate L1 activity
in different assays and cellular contexts.
In addition, our finding that non-targeting control
siRNAs may affect L1 retrotransposition may have
relevance not only for interpreting L1 assays but also
for the development of therapeutic siRNA, a treat-
ment option currently being optimized for numerous
conditions including cancer [81–83]. As L1 is thought
to have deleterious effects, caution is warranted in
the design and testing of candidate molecules
intended for clinical use.
Effects on heterologous promoters can be monitored
in order to select one unaffected by experimental condi-
tions. However, as some L1 reporters have up to three
such promoters and may also be susceptible to artifacts
arising from EBNA1 and the EBV origin of replication,
this approach could be costly in terms of labor and re-
sources and is therefore impractical for high throughput
screening utilizing multiple experimental conditions.
However, assuming suitable promoters could be identi-
fied for each experimental condition, a combination of
native and constitutive L1 promoters with corresponding
assays to monitor cell growth may be employed to suc-
cessfully identify effects on L1 activity.
Several recently developed methods may offer some al-
ternatives [84, 85]. The L1 element amplification proto-
col (LEAP assay) allows investigation of in vitro ORF2p
enzymatic activity from L1 RNP particles purified from
cells expressing engineered L1 reporters [86, 87]. The
addition of purified host factors to these reactions would
allow investigation of direct effects on ORF2p reverse
transcriptase activity while avoiding some of the is-
sues described herein. Next-generation sequencing
methods [85, 88] including retrotransposon capture
sequencing (RC-seq) [89, 90], as well as novel ap-
proaches for validation such as droplet digital PCR [91],
offer the possibility of examining endogenous L1 ele-
ments in their native chromatin environment. These
technical advances should facilitate investigation of
the host factors that delimit L1 tissue specificity and
various aspects of retrotransposition.
Conclusions
Our results indicate that the use of exogenous gene ex-
pression or siRNA with engineered L1 reporter assays
may introduce confounding variables. Thus, investiga-
tion of the roles of host factors in L1 retrotransposition
when using these techniques will require extra efforts to
ensure that observed results are not artifacts.
Methods
Plasmid construction
Bacterial expression vectors for ORF1p (pET32aΔN-
ORF1-6xHis) were made as follows. First, an existing
ORF1 vector [92] with the backbone of pET32a was al-
tered to remove the following: the pET32a N-terminal
TRX and 6xHis tags, an engineered TEV sequence that
had previously destroyed the multiple cloning region, a
truncated ORF1 mutant and remnant sequence 3′ to
ORF1 that was retained from prior subcloning. A
remaining 3′ EcoRI site and the C-terminal 6xHis tag
were left intact, and BamH1 site was inserted 5′ of the
EcoRI site. These changes were made using the Quik-
Change II kit (Agilent) with the forward deletion primer
5′TTAACTTTAAGAAGGAGATATACATGGATCCAAT
CCCGGGACGCGTG and reverse deletion primer 5′
CACGCGTCCCGGGATTGGATCCATGTATATCTCCT
TCTTAAAGTTAA. The resulting clone was designated
pET32aΔN. Full-length ORF1 PCR-generated amplicons
were created from the previously described pORF1-
Flag mammalian expression vector [31] using a high-
fidelity DNA polymerase with the forward primer 5′
CGCGGATCCATGGGGAAAAAACAGAACAG contain-
ing a 5′ BamH1 site, and reverse primer 5′
GCCGGAATTCGCCGCCGCCCATTTTGGCATGATTT
TGC, which introduced a spacer of three glycines between
the end of ORF1 and the 3′ EcoRI sequence (the Flag se-
quence was not retained). The ORF1p amplicon was
inserted into pET32aΔN via the BamH1 and EcoRI sites.
The BamH1 site was subsequently deleted to move the
ATG start site of ORF1 to an optimal distance from the
ribosomal binding site in pET32aΔN and destroy an alter-
nate out-of-frame ATG start site that encompassed the 5′G
of the BamH1 site. These changes were made using the
QuikChange II kit (Agilent) with the forward primer 5′
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATA-
CATATGGGGAAAAAACAGAACAG and the reverse pri-
mer 5′CTGTTCTGTTTTTTCCCCATATGTATATCTCC
TTCTTAAAGTTAAACAAAATTATTTC. In an attempt
to reduce translation initiation at internal non-canonical
Shine-Dalgarno sequences in ORF1, we also created silent
mutations at D123 and N126, changing the existing codons
to GAC and AAC, respectively. ORF1p S/T-P motif muta-
tions were created using sequential site-directed mutagen-
esis with the QuikChange II kit (Agilent).
Bacterial expression plasmids for p38δ-F324S and
D176A (pRSET-A-6xHis-p38δ-StrepII) were made by
first generating a p38δ-WT amplicon via PCR using a
high-fidelity polymerase and the forward primer 5′
CGCGGATCCGCAATGAGCCTCATCCGGAAAAAGG
GCTTCTACAAGCAGG and reverse primer 5′GCCG
GAATTCTCACTTCTCGAACTGGGGGTGGCTCCAT
GCGCCCAGCTTCATGCCACTCCG on the Addgene
template plasmid # 20523 (pWZL Neo Myr Flag
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MAPK13, a gift from William Hahn & Jean Zhao [93]).
The amplicon containing a 5′ BamHI and Kozak se-
quence and a 3′ Gly/Ala spacer upstream of a StrepII
tag, stop codon and EcoRI site was then inserted into
pRSET-A (ThermoFisher) via the BamHI and 3′ EcoRI
sites in the multiple cloning region. Point mutations
were created via site-directed mutagenesis with the
QuikChange II kit (Agilent).
The mammalian expression vector for p38δ-WT
(pcDNA-Zeo (3.1+)-p38δ-StrepII) was made by PCR
amplification of the Addgene plasmid # 20523 [93] using
the same forward and reverse primers noted above for
making pRSET-A-6xHis-p38δ-StrepII, followed by inser-
tion into the multiple cloning region of pcDNA 3.1/Zeo
(+) (ThermoFisher). Point mutations to make F324S and
D176A were created via site-directed mutagenesis with
the QuikChange II kit (Agilent).
Mammalian expression vectors for MKK3b2E (pcDNA3
Flag MKK3b (Glu) [58]; Addgene plasmid # 50449) and
MKK62E (pcDNA3-Flag MKK6 (Glu) [60]; Addgene plas-
mid # 13518) were both gifts from Roger Davis.
All cloned inserts were verified with DNA sequencing.
DNA intended for cell culture transfections was purified
using the endotoxin-free NucleoBond Xtra Midi plasmid
DNA purification kit (Macherey-Nagel).
Protein expression
ORF1p proteins were expressed in Rosetta (DE3) cells
(Novagen) transformed with pET32aΔN-ORF1-His. Over-
night starter cultures of 15–25 ml LB medium with
100 μg/ml ampicillin and 34 μg/ml chloramphenicol were
grown at 37 °C on a rotary shaker at 250 rpm. The follow-
ing day, cultures were expanded 20 to 50 fold with LB
medium containing the indicated antibiotics and grown at
37 °C on a rotary shaker at 250 rpm to an OD600 of ap-
proximately 0.6. Cultures were then induced with 1 mM
isopropyl-beta-D-thiogalactopyranoside (IPTG), grown for
an additional 4–6 h, pelleted via centrifugation and frozen
at -80 °C. At the time of purification, cells were thawed
and resuspended in 5 ml per gram pellet of a buffer con-
taining 100 mM Tris–HCl (pH 8.0), 100 mM NaCl, and
1 mg/ml lysozyme and incubated on ice for 30 min. Fol-
lowing lysozyme digest, lysates were supplemented with
400 mM NaCl (for final concentration of 500 mM), 2 mM
dithiothreitol (DTT) and 15 mM imidazole. The lysates
were pulled through a 19–21gauge syringe approximately
12 times and centrifuged at 10,000 × g at 4 °C for 20 min.
Cleared lysates were applied to Ni-NTA superflow resin
(Qiagen) previously equilibrated with lysis buffer (post
lysozyme concentrations), rotated for 1 h at 4 °C, washed
4 times with 20 mM Tris–HCl (pH 7.4), 500 mM NaCl,
and 25 mM imidazole, then eluted 4 times with 20 mM
Tris–HCl (pH 7.4), 500 mM NaCl, 250 mM imidazole,
10% glycerol and 2 mM DTT at a ratio of 1 μl elution
buffer per 1 ml of original culture volume. Proteins were
dialyzed overnight against 50 mM Tris–HCl (pH 80),
350 mM NaCl, 15 mM KCl, 5 mM MgCl2, 20% glycerol,
2 mM DTT, and 1 mM phenylmethylsulfonyl fluoride
(PMSF).
p38δ-F324S and p38δ-D176A proteins were expressed
in Rosetta2 (DE3) cells (Novagen) transformed with
pRSET-A-His-p38δ-StrepII and processed as described
above for ORF1p except 150 mM NaCl was used in the
dialysis buffers. Note: we found that omission of DTT in
the elution and/or dialysis steps of p38δ purification re-
sulted in an inactive protein, consistent with a previous
report [94].
All proteins were quantified via denaturing gel electro-
phoresis with a standard curve of bovine serum albumin
followed by staining with Coomassie G-250 PageBlue
(ThermoFisher) and analysis with ImageJ [95].
Kinase assays
In vitro kinase reactions contained 85 nM p38δ or p38δ
dialysis buffer and 200 μM ORF1p in 50 mM Tris–HCl
(pH 7.4), 10 mM MgCl2, 0.1 mM EGTA, 150 mM NaCl,
2 mM DTT, and 2 mM ATP spiked with approximated
0.5 × 106 c.p.m./nmol [γ-32P]-ATP (PerkinElmer). Reac-
tions were incubated at 37 °C for 15 min and stopped
with the addition of loading buffer supplemented with
EDTA to a final concentration of 50 mM. Samples were
heated to 98 °C for 10 min then separated via denaturing
gel electrophoresis. Gels were dried and exposed using
Phosphorimaging.
Cell culture
HeLa-JVM cells (a kind gift from Dr. John Moran) were
cultured in Dulbecco’s Modified Eagle Media (DMEM)
with high glucose and pyruvate (Gibco, ThermoFisher)
supplemented with 10% Fetal Bovine Serum (Gibco,
ThermoFisher, certified heat inactivated, US origin) and
100 Units/ml penicillin and 100 μg/ml streptomycin
from a combined formulation (Gibco, ThermoFisher).
The cells were maintained at 37 °C in a standard incuba-
tor and passaged using 0.05% Trypsin-EDTA (Gibco,
ThermoFisher).
L1 reporter assays
Culture plates were seeded with HeLa-JVM cells in
antibiotic-free DMEM with 10% FBS at a density to
achieve approximately 50% confluency in 24 h, at which
time cells were transfected using a ratio of 3 μl Fugene6
(Promega) per 1 μg DNA. For the G418-based assay,
cells were seeded in 6-well plates and transfected with
500 ng JM101 and 500 ng pcDNA per well, allowed to
grow for 72 h, then selected with media containing
400 μg/ml G418 sulfate (Geneticin, Gibco, Thermo-
Fisher) for 10–12 days. Cells were then washed with
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phosphate buffered saline (PBS) and fixed with 2% for-
maldehyde and 0.2% glutaraldehyde in PBS for at least
30 min at room temperature. Cells were then washed
twice with PBS, stained with KaryoMAX Giemsa (Gibco,
ThermoFisher) for 1 h at room temperature, rinsed
briefly twice with 50% ethanol and then water. For lucif-
erase assays, cells were seeded in 24-well plates and
transfected with 200 ng of reporter and 200 ng pcDNA-
p38δ per well or 25 ng pcDNA-MKK3b2E or pcDNA-
MKK62E. Lysates were harvested 4 days post transfection
and processed in 96-well plates with the Dual-Luciferase
Reporter Assay System (Promega) according to manu-
facturer’s protocol.
Transfection efficiency assays
HeLa-JVM cells were plated in 8-well glass bottom μ-Slides
(ibidi GmbH, Martinsried, Germany) in antibiotic-free
DMEM with 10% FBS at a density to achieve approxi-
mately 60% confluency per well in 24 h. Wells with siRNA
were reverse transfected as described in the following sec-
tion. After a 24-h incubation, cells were transfected as de-
scribed above with a pcDNA-EGFP expression plasmid (for
siRNA wells) or cotransfected with pcDNA-EGFP and each
pcDNA-p38δ expression plasmid. The ratio of DNA to sur-
face area was identical to that used in the 6-well plates.
After 24 h, cells were rinsed twice with PBS, then DMEM
sans phenol red plus 10% FBS was added to each well.
Cells were visualized with a Keyence BioRevo BZ-II 9000
digital microscope fitted with a Nikon PlanApo 4×/0.20 ob-
jective lens and 49002 ET-EGFP filter set from Chroma
(Bellows Falls, VT). Tiled images covering approximately
70% of each well were stitched with Keyence BZ-II
Analyzer software, and total fluorescence in each stitched
image was quantified in Fiji software using the Integrated
Density function.
siRNA knockdown
HeLa-JVM cells were plated in antibiotic-free DMEM
with 10% FBS at a density to achieve approximately
60% confluency in 24 h and reverse transfected per man-
ufactures’ protocol using Lipofectamine RNAiMAX
(ThermoFisher) at a ratio of 1 μl RNAiMAX per 8 pmols
siRNA. All siRNAs were purchased from Dharmacon:
NTC #3, NTC #5 and SMARTpool siRNA against p38δ
(Dharmacon, M-003591-02-0005). Following reverse
transfection, cells were incubated for 24 h, then siRNA-
containing media was removed and replaced with fresh
antibiotic-free plating media with 10% FBS at the time of
transfection with L1 reporters as described above.
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